L2 Bio, LLC Launches C-ROW Site Beta: A Breakthrough Research Project in Costa Rica Targeting Osteoarthritis
Innovative Participant-Funded Study Harnesses Enhanced Autologous Adipose-Derived Stem Cells to Combat Degenerative Joint Disease
ESCAZU, COSTA RICA, June 1,  2026 — L2 Bio, LLC has formally announced the launch of the C-ROW Site Beta (C-ROW), an innovative, participant-funded research project based in Costa Rica welcoming the safety and convenience of utilizing local participation of your USA or Canadian based doctor. The study centers on the use of enhanced autologous adipose-derived stem cells (ADSCs) to address the debilitating progression of osteoarthritis. [Read more…]
L2 Bio Seeks Principal Investigators for FDA-Approved Phase 2B Clinical Trial of Adipose-Derived Stem Cell Treatment for Crohn’s Disease
HENDERSON, NV – June 12, 2025, www.L2Bio.com – L2 Bio, is the clear leader in adipose-derived stem cell banking. L2 Bio is the only AD-Stem Cell Banking company with an FDA Approved Investigational New Drug. L2 is actively recruiting qualified Principal Investigators for its recently FDA-approved Phase 2B clinical trial. This groundbreaking study will investigate a novel intravenous (IV) delivery of adipose-derived stem cells (ADSCs or ASCs) for the treatment of Crohn’s Disease utilizing autologous or first-degree blood relative sourced Adipose Derived Mesenchymal Stem Cells (AD-MSCs). A simple, virtually painless, 15-minute procedure from the subject or donor is likely to produce enough stem cells to treat the subject for the duration of the trial and likely the remainder of their life if necessary. [Read more…]
Diversifying Cord Blood Banking through Adipose-Derived Stem Cell Storage
The global cord blood banking industry has been rapidly maturing in recent years. In part, this has been caused by changes in processing, storage, and transplantation technologies. These changes require executives and industry decision-makers to have a firm understanding of emerging trends.
One of the most notable cord blood industry trends has been a diversification of services. Put simply, cord blood banks are becoming diversified stem cell biobanks. [Read more…]
Key Market Leaders for Adipose-Derived Mesenchymal Stem Cell (MSC) Storage
In addition to cord tissue storage, many cord blood banks are now investigating the addition of adipose-derived stem cell storage.
It is a logical product extension for cord blood banks, given that a range of collection, processing, and storage equipment is already present within the facility.
Additionally, conversion costs to allow for adipose-derived stem cell storage can be as low as USD $100,000 to $150,000.
The conversion of a cord blood facility to be able to offer adipose-derived stem cell storage can be efficiently accomplished through collaboration with a specialist in the area of adipose tissue extraction and storage.
Companies such as American Cryostem in the United States have been willing to partner with cord blood banks to assist them with adding adipose-derived MSC storage as a service.
Leading Companies Offering Mesenchymal Stem Cell (MSC) Storage
Below is an analysis of both diversified cord blood banks and specialty companies that currently offer adipose-derived stem cell storage. [Read more…]